Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Comprehensive Guide to CSA C22.2 No. 60601-2-31-09 (2019): Safety and Performance Standards for External Cardiac Pacemakers
Understanding the Canadian adaptation of IEC 60601-2-31 for external cardiac pacemaker safety and essential performance requirements.
Scope and Application
CSA C22.2 No. 60601-2-31-09 (2019) is the Canadian adoption of IEC 60601-2-31:2008, with national deviations that reflect Canadian regulatory requirements and healthcare practices. This standard applies to the basic safety and essential performance of external cardiac pacemakers that incorporate an internal power source. Such devices are used to deliver therapeutic electrical stimulation to the heart via transcutaneous or transvenous pacing leads, typically in acute care settings, emergency departments, operating rooms, or during patient transport. The standard specifically excludes implantable pacemakers, defibrillators, and pacemaker systems that rely solely on external mains power for continuous operation.
Tip: While the standard focuses on professional healthcare environments, it also addresses the unique risks associated with transport and home care applications when a pacemaker is intended for those contexts.
Applicability
This standard is intended for manufacturers, testing laboratories, and regulatory bodies involved in the design, verification, and certification of external cardiac pacemakers. It covers equipment that provides temporary pacing through external electrodes (transcutaneous) or externalised pacing wires (temporary transvenous). The scope also includes integrated physiological monitoring functions, alarms, and data logging that are part of the pacemaker system.
Relation to the Collateral Standards
The standard is used in conjunction with CSA C22.2 No. 60601-1 (or CAN/CSA-C22.2 No. 60601-1 Edition 3) and applicable collateral standards such as CSA C22.2 No. 60601-1-2 (EMC) and CSA C22.2 No. 60601-1-8 (alarms). It modifies and supplements these base standards to address the specific hazards and performance characteristics of external cardiac pacemakers.
Key Technical Requirements
CSA C22.2 No. 60601-2-31-09 (2019) establishes both safety requirements and essential performance criteria. Essential performance includes functions whose failure or degradation would cause an unacceptable risk to the patient. For external pacemakers, these functions typically encompass pacing output accuracy, sensing performance, protection against defibrillation, and alarm systems.
Warning: Failure to meet any essential performance requirement may render the device unsafe for clinical use, regardless of compliance with other safety clauses.
Protection Against Electrical Hazards
Due to the direct electrical connection to the heart via pacing leads, the standard imposes stringent limits on leakage currents and dielectric strength. Patient leakage currents under normal and single-fault conditions are required to be below 10 µA in normal conditions and 50 µA in single-fault conditions. Additionally, the pacemaker must withstand the application of a defibrillator discharge without sustaining damage that would compromise essential performance.
Pacing Output Accuracy and Stability
The standard requires the pacing rate, pulse amplitude, and pulse duration to be within defined tolerances under all operating conditions (temperature, battery voltage, lead impedance). For example, the rate must be accurate to ±1% of the set value or ±1 pulse per minute, whichever is greater. Pulse amplitude must remain within ±10% or ±0.2 V of the set value, and pulse duration within ±1% or ±0.1 ms.
Sensing Performance
Cardiac pacemakers must reliably sense intrinsic cardiac activity to avoid competitive pacing that could induce arrhythmias. The standard specifies minimum sensing sensitivity (typically 0.5 mV for intracardiac signals) and requires the device to correctly detect R-waves while rejecting T-waves, myopotentials, and electromagnetic interference. Refractory periods and blanking intervals are also defined.
Protection Against Defibrillation
A critical requirement is the ability to survive external defibrillation without loss of essential function. The pacemaker must withstand a defibrillation discharge of up to 360 J (monophasic or biphasic) applied via the pacing electrodes. After the event, the device must resume pacing within 3 seconds and without any parameter shift beyond the tolerances.
Success: Pacemakers meeting this requirement can be safely used in emergency situations where defibrillation is necessary, without added patient risk.
Alarms and Warning Systems
Alarms are classified as high priority (life-threatening conditions such as loss of pacing output, lead disconnection, or low battery) and medium priority (e.g., impedance out of range). The standard mandates visual and audible indications that are discriminable under clinical ambient conditions. Alarm delays and reset behaviour are specified to prevent nuisance alarms while ensuring timely notification.
Implementation and Testing Considerations
Manufacturers must integrate the technical requirements into the design lifecycle from concept phase. The standard prescribes both type testing and routine testing for production units.
| Parameter | Requirement (per Standard) | Test Condition | Typical Tolerance |
|---|---|---|---|
| Pacing Rate | ±1 % or ±1 ppm | 37 °C, 500 Ω load | ±1 % at 60 ppm |
| Pulse Amplitude | ±10 % or ±0.2 V | 500 Ω load, nominal voltage | ±0.2 V for 2 V setting |
| Pulse Duration | ±1 % or ±0.1 ms | 500 Ω load | ±0.1 ms at 1 ms setting |
| Sensing Sensitivity | ±20 % of threshold | Simulated R-wave, 1 ms duration | ±20 % at 2 mV setting |
| Patient Leakage Current (NC) | ≤ 10 µA | Per IEC 60601-1 measurement | — |
| Defibrillation Survival | 360 J, resume pacing ≤3 s | Monophasic & biphasic waveform | — |
Environmental Testing
The standard includes climatic and mechanical tests: operating temperature range (typically 10 °C to 40 °C), storage temperatures, humidity (93 % RH non-condensing), vibration, and drop testing. For transportable equipment, it also addresses shock and impact during normal handling.
Electromagnetic Compatibility (EMC)
CSA C22.2 No. 60601-2-31-09 (2019) refers to the collateral standard CSA C22.2 No. 60601-1-2 for EMC, but adds specific immunity levels for electric and magnetic fields typical of hospital environments. Pacemakers must maintain essential performance when subjected to interference from electrosurgery units, MRI stray fields, and wireless communication devices.
Danger: Inadequate EMC immunity can cause pacing inhibition or false sensing, leading to patient harm. Planning for 20 V/m immunity up to 2.5 GHz is recommended.
Compliance and Certification Notes
Compliance with CSA C22.2 No. 60601-2-31-09 (2019) is mandatory for medical devices sold in Canada that fall within its scope. The standard is recognised by Health Canada under the Medical Devices Regulations (SOR/98-282).
Conformity Assessment
Most manufacturers seek third-party certification through a CSA-accredited testing laboratory. The evaluation includes:
- Full type testing per all applicable clauses
- Review of the risk management file (aligned with ISO 14971)
- Examination of instructions for use and technical documentation
- Verification of production quality system (e.g., ISO 13485, MDSAP)
Canadian Deviations vs. International Edition
The CSA edition incorporates national modifications, such as:
- Requirement for dual-language (English/French) labelling and accompanying documents
- More stringent limits on patient leakage current for some electrode types
- Inclusion of additional marking requirements per Canadian Electrical Code
Tip: When designing for global markets, it is efficient to create a core design that meets the most stringent national deviations, then adapt the documentation for each region.
Maintaining Compliance
Manufacturers must monitor post-market surveillance and report any incidents related to safety or essential performance to Health Canada. The standard also requires periodic re-testing if significant design changes are introduced. The 2019 edition reaffirmed the earlier 2009 version with updated references and editorial corrections, so devices certified to CSA C22.2 No. 60601-2-31-09 (2019) remain current.
In summary, CSA C22.2 No. 60601-2-31-09 (2019) provides a comprehensive framework for the safety and essential performance of external cardiac pacemakers. Adherence to its requirements ensures that devices operate reliably under clinical conditions and protect both patients and operators from electrical and other hazards.
Success: Certification to this standard not only fulfills Canadian regulatory obligations but also demonstrates a manufacturer’s commitment to device safety and clinical performance.
Frequently Asked Questions
Q: Is CSA C22.2 No. 60601-2-31-09 (2019) identical to IEC 60601-2-31:2008?
A: It is based on IEC 60601-2-31:2008 but includes Canadian national deviations concerning dual-language labeling, specific leakage current limits, and additional marking requirements. The technical safety and performance requirements are largely harmonised, making it possible for a device certified to the IEC version to be adapted for Canada with supplementary documentation and testing.
A: It is based on IEC 60601-2-31:2008 but includes Canadian national deviations concerning dual-language labeling, specific leakage current limits, and additional marking requirements. The technical safety and performance requirements are largely harmonised, making it possible for a device certified to the IEC version to be adapted for Canada with supplementary documentation and testing.
Q: Does this standard cover pacemakers used in home care?
A: Yes, if the device is intended for use by non-professionals, the standard includes additional requirements for usability and alarm clarity. The manufacturer must specify the intended patient population and environment in the risk management file.
A: Yes, if the device is intended for use by non-professionals, the standard includes additional requirements for usability and alarm clarity. The manufacturer must specify the intended patient population and environment in the risk management file.
Q: What is the significance of the “internal power source” requirement?
A: It means the pacemaker should have a battery that supplies the energy for pacing, separate from or in addition to any mains connection. This ensures portability and that the device can operate during patient transport or power failures without losing pacing function. The standard also prescribes low-battery indicators and automatic switchover to backup power.
A: It means the pacemaker should have a battery that supplies the energy for pacing, separate from or in addition to any mains connection. This ensures portability and that the device can operate during patient transport or power failures without losing pacing function. The standard also prescribes low-battery indicators and automatic switchover to backup power.
Q: How often should a certified pacemaker be re-evaluated?
A: Re-evaluation is required upon any significant change in design, manufacturing process, or intended use that could affect safety or essential performance. CSA recommends periodic review of the technical file (every 3–5 years) to account for new risk information or regulatory updates.
A: Re-evaluation is required upon any significant change in design, manufacturing process, or intended use that could affect safety or essential performance. CSA recommends periodic review of the technical file (every 3–5 years) to account for new risk information or regulatory updates.
Last updated: 2026